ADXS vs. ADIL, MBRX, MNPR, VAXX, ERNA, NCNA, UPC, ABVC, ADXN, and OGEN
Should you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Adial Pharmaceuticals (ADIL), Moleculin Biotech (MBRX), Monopar Therapeutics (MNPR), Vaxxinity (VAXX), Eterna Therapeutics (ERNA), NuCana (NCNA), Universe Pharmaceuticals (UPC), ABVC BioPharma (ABVC), Addex Therapeutics (ADXN), and Oragenics (OGEN). These companies are all part of the "pharmaceutical preparations" industry.
Ayala Pharmaceuticals (NASDAQ:ADXS) and Adial Pharmaceuticals (NASDAQ:ADIL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
Adial Pharmaceuticals received 108 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 58.06% of users gave Adial Pharmaceuticals an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
In the previous week, Adial Pharmaceuticals had 4 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.60 beat Ayala Pharmaceuticals' score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the news media.
Ayala Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Adial Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.
7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 14.5% of Adial Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Adial Pharmaceuticals' return on equity of -170.85% beat Ayala Pharmaceuticals' return on equity.
Adial Pharmaceuticals has lower revenue, but higher earnings than Ayala Pharmaceuticals.
Summary
Adial Pharmaceuticals beats Ayala Pharmaceuticals on 9 of the 11 factors compared between the two stocks.
Get Ayala Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ayala Pharmaceuticals Competitors List
Related Companies and Tools
